| scholarly article | Q13442814 |
| P50 | author | Shahrokh Shariat | Q7462263 |
| Pierre I Karakiewicz | Q97332033 | ||
| Arthur I. Sagalowsky | Q114316665 | ||
| Raheela Ashfaq | Q114316683 | ||
| Seth P. Lerner | Q114316685 | ||
| Ganesh S Palapattu | Q114404137 | ||
| Rick H. Cote | Q46575944 | ||
| Yair Lotan | Q61862568 | ||
| P2860 | cites work | Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder | Q80212552 |
| Cancer statistics, 2006 | Q29615133 | ||
| The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. | Q34039879 | ||
| Evaluating the yield of medical tests | Q34277948 | ||
| Microarrays as cancer keys: an array of possibilities. | Q34739207 | ||
| Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer | Q35065401 | ||
| p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder | Q36079809 | ||
| Tissue microarrays: bridging the gap between research and the clinic | Q36184792 | ||
| Bladder cancer clinical trials | Q36194232 | ||
| P53 as a prognostic marker for bladder cancer: a meta-analysis and review. | Q36243745 | ||
| Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma | Q38448798 | ||
| p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer | Q38448806 | ||
| Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors | Q39605793 | ||
| Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy | Q43564933 | ||
| Immunohistochemical localization and semi-quantitation of hepatic tamoxifen-DNA adducts in rats exposed orally to tamoxifen | Q43750888 | ||
| Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience | Q43806537 | ||
| Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer | Q44009131 | ||
| The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial | Q45146420 | ||
| Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. | Q45967681 | ||
| Accumulation of nuclear p53 and tumor progression in bladder cancer. | Q45977663 | ||
| Regression modeling of competing crude failure probabilities | Q47671166 | ||
| Precystectomy nomogram for prediction of advanced bladder cancer stage. | Q53006807 | ||
| Nomograms provide improved accuracy for predicting survival after radical cystectomy. | Q53013621 | ||
| Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. | Q53563491 | ||
| Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. | Q53601758 | ||
| p53 and treatment of bladder cancer | Q59079146 | ||
| Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression | Q72066713 | ||
| Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC | Q72240687 | ||
| Cystectomy for bladder cancer: a contemporary series | Q73637983 | ||
| Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1 | Q73936669 | ||
| Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer | Q74449043 | ||
| Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium | Q79329951 | ||
| Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy | Q79772772 | ||
| Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era | Q79823507 | ||
| Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer | Q79976034 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| biomarker | Q864574 | ||
| P304 | page(s) | 315-325 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy | |
| P478 | volume | 112 |
| Q30360896 | A Dual-Modality System for Both Multi-Color Ultrasound-Switchable Fluorescence and Ultrasound Imaging. |
| Q27022638 | A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential |
| Q30640970 | A network pharmacology approach to evaluating the efficacy of chinese medicine using genome-wide transcriptional expression data |
| Q89516462 | A panel of five plasma proteins for the early diagnosis of hepatitis B virus-related hepatocellular carcinoma in individuals at risk |
| Q33439263 | A systematic review of the tools available for predicting survival and managing patients with urothelial carcinomas of the bladder and of the upper tract in a curative setting |
| Q37685558 | Are nomograms needed in the management of bladder cancer? |
| Q38413564 | Bilharzial vs non‐bilharzial related bladder cancer: pathological characteristics and value of cyclooxygenase‐2 expression |
| Q37987066 | Biomolecular predictors of urothelial cancer behavior and treatment outcomes |
| Q36108115 | Bladder cancer: a simple model becomes complex |
| Q84039276 | Bladder cancer: nomogram aids clinical decision making after radical cystectomy |
| Q38170812 | Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder |
| Q37407271 | C5a receptor expression is associated with poor prognosis in urothelial cell carcinoma patients treated with radical cystectomy or nephroureterectomy |
| Q37445971 | Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach |
| Q37279010 | Combining a molecular profile with a clinical and pathological profile: biostatistical considerations |
| Q30438089 | Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer |
| Q37053926 | Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study |
| Q43555869 | Constructing prognostic model incorporating the 2004 WHO/ISUP classification for patients with non-muscle-invasive urothelial tumours of the urinary bladder |
| Q37789085 | Current chemotherapeutic options for the treatment of advanced bladder cancer: A review |
| Q37974674 | Current status of molecular markers for prognostication and outcome in invasive bladder cancer |
| Q37269864 | Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancer |
| Q39592589 | Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis |
| Q38650679 | Emerging Bladder Cancer Biomarkers and Targets of Therapy |
| Q27021371 | Emerging critical role of molecular testing in diagnostic genitourinary pathology |
| Q34537170 | Expression profiling for bladder cancer: strategies to uncover prognostic factors. |
| Q38440895 | External validation of online predictive models for prediction of cancer-specific mortality and all-cause mortality in patients with urothelial carcinoma of the urinary bladder |
| Q86123547 | Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: preliminary results |
| Q38196442 | Functional polymorphisms in the matrix metalloproteinase genes and their association with bladder cancer risk and recurrence: a mini-review. |
| Q39579247 | H2AX phosphorylation level in peripheral blood mononuclear cells as an event-free survival predictor for bladder cancer |
| Q40897221 | Identification of genes correlated with early-stage bladder cancer progression |
| Q37902697 | Immunohistochemical biomarkers for bladder cancer prognosis |
| Q42343423 | Liquid biopsies in bladder cancer-did we find the Holy Grail for biomarker analyses? |
| Q84730836 | Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy |
| Q43196454 | Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial |
| Q37812609 | Management of upper urinary tract urothelial carcinoma |
| Q37864524 | Matrix metalloproteinases and their clinical relevance in urinary bladder cancer |
| Q37339723 | Molecular biomarkers for urothelial carcinoma of the bladder: challenges in clinical use. |
| Q37967115 | Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? |
| Q37575626 | Molecular determinants of tumor recurrence in the urinary bladder |
| Q91794064 | Molecular markers in bladder cancer |
| Q38520403 | Molecular markers in bladder cancer: Novel research frontiers |
| Q52942124 | Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different? |
| Q26744343 | Molecular substratification of bladder cancer: moving towards individualized patient management |
| Q39359483 | Multiplatform Biomarker Discovery for Bladder Cancer Recurrence Diagnosis. |
| Q39442878 | NMIBC risk calculators: how useful are they for the practicing urologist and how can their clinical utility be improved? |
| Q38424934 | Novel biomarkers to predict response and prognosis in localized bladder cancer |
| Q41612483 | Nuclear features of infiltrating urothelial carcinoma are distinguished from low-grade noninvasive papillary urothelial carcinoma by image analysis |
| Q53094880 | P21 and p27 Immunoexpression in Upper Urinary Tract Urothelial Carcinomas. |
| Q30437629 | Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat |
| Q30968069 | Pitfalls and Limitations of Diffusion-Weighted Magnetic Resonance Imaging in the Diagnosis of Urinary Bladder Cancer |
| Q38424919 | Potential role for targeted therapy in muscle-invasive bladder cancer: lessons from the cancer genome atlas and beyond. |
| Q37181866 | Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers |
| Q37103989 | Predicting survival after radical cystectomy for bladder cancer |
| Q53063306 | Prediction of recurrence of non muscle-invasive bladder cancer by means of a protein signature identified by antibody microarray analyses. |
| Q38230912 | Predictive markers in bladder cancer: do we have molecular markers ready for clinical use? |
| Q54590034 | Primary adenocarcinoma of the urinary bladder: value of cell cycle biomarkers. |
| Q37897483 | Prognostic factors for upper urinary tract urothelial carcinoma |
| Q38049692 | Prognostic value of cell-cycle regulation biomarkers in bladder cancer. |
| Q55263257 | Prognostication in Patients Treated with Radical Cystectomy for Urothelial Bladder Carcinoma: A New Simplified Model Incorporating Histological Variants. |
| Q44293813 | Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy |
| Q87765407 | Quantitation of rare circulating tumor cells by folate receptor α ligand-targeted PCR in bladder transitional cell carcinoma and its potential diagnostic significance |
| Q34155874 | Quantitative apparent diffusion coefficient measurements obtained by 3-Tesla MRI are correlated with biomarkers of bladder cancer proliferative activity |
| Q36623107 | Risk of cancer-specific mortality following recurrence after radical nephroureterectomy |
| Q36419132 | Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling |
| Q82739755 | Role of biomarkers to predict outcomes and response to therapy |
| Q33583048 | SKIP expression is correlated with clinical prognosis in patients with bladder cancer |
| Q36124883 | Statistical consideration for clinical biomarker research in bladder cancer |
| Q35594733 | The promise of methylation on beads for cancer detection and treatment. |
| Q36607766 | Tumor markers in prostate cancer I: blood-based markers |
| Q45948761 | Twenty-year experience of radical cystectomy for bladder cancer in a medium-volume centre. |
| Q36956211 | UBE2C is a marker of unfavorable prognosis in bladder cancer after radical cystectomy |
| Q43829007 | UPK3A: a promising novel urinary marker for the detection of bladder cancer |
| Q38536270 | Urine biomarkers of schistosomiais and its associated bladder cancer |
| Q35076360 | Use of nomograms for predictions of outcome in patients with advanced bladder cancer |
| Q39621585 | ncRAN, a newly identified long noncoding RNA, enhances human bladder tumor growth, invasion, and survival |
| Q50181214 | pH-Responsive fluorescent graphene quantum dots for fluorescence-guided cancer surgery and diagnosis. |
Search more.